Abivax (ABVX) Projected to Post Earnings on Monday

Key Points

• Abivax is set to announce its Q2 2025 earnings on August 11th, with expectations of a loss of ($0.92) per share and revenue of $1.19 million.
• Shares of ABVX opened at $70.68, with a 1-year high of $75.51 and a low of $4.77, indicating significant volatility in stock performance.
• Several institutional investors, including Millennium Management and Woodline Partners, have recently increased their positions in Abivax, showing growing confidence among investors.

Abivax (NASDAQ:ABVX - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Monday, August 11th. Analysts expect Abivax to post earnings of ($0.92) per share and revenue of $1.19 million for the quarter.

Abivax Stock Performance

Shares of NASDAQ:ABVX traded up $0.11 on Friday, hitting $70.13. 667,272 shares of the company were exchanged, compared to its average volume of 622,877. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. The stock's 50 day moving average price is $22.64 and its 200 day moving average price is $12.08. Abivax has a 1-year low of $4.77 and a 1-year high of $75.51.

Hedge Funds Weigh In On Abivax

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC grew its position in shares of Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock worth $6,171,000 after buying an additional 56,235 shares in the last quarter. Woodline Partners LP lifted its stake in Abivax by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock worth $1,262,000 after purchasing an additional 153,788 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on ABVX. Lifesci Capital increased their price target on shares of Abivax from $45.00 to $101.00 and gave the stock an "outperform" rating in a report on Wednesday, July 23rd. Citigroup reissued a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. Leerink Partners set a $74.00 target price on Abivax and gave the stock an "outperform" rating in a report on Wednesday, July 23rd. Morgan Stanley raised Abivax from an "equal weight" rating to an "overweight" rating and set a $71.00 price target for the company in a report on Wednesday, July 23rd. Finally, JMP Securities increased their price target on shares of Abivax from $33.00 to $95.00 and gave the stock a "market outperform" rating in a report on Wednesday, July 23rd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $92.33.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.